Fortitude Advisory Group’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-24
Closed -$2K 1625
2021
Q4
$2K Buy
+24
New +$1.4K ﹤0.01% 1423

Other funds holding HTGM

Fortitude Advisory Group's HTGM Position: Q1 2022 in Review

Fortitude Advisory Group sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q1 2022, closing a stake of 24 shares — an estimated $2K sold.

Fortitude Advisory Group first reported a position in HTGM in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 21 funds tracked by Wall St. Rank hold HTGM as of Q1 2022.

  • Fortitude Advisory Group reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Fortitude Advisory Group sold 24 HTG Molecular Diagnostics, Inc. Common Stock shares in Q1 2022, an estimated $2K.
  • Fortitude Advisory Group first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Fortitude Advisory Group's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $2K in Q4 2021.
  • 21 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q1 2022.

Based on Fortitude Advisory Group's 13F filing for Q1 2022, filed 25 May 2022.